Jun 2026 (Q2 FY26) — Aug 5, 2026
Vanda Q2 FY26 — Strong FENAPT Growth and Pipeline Progress
Read the full callVanda (VNDA) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Vanda earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 50.5 | −3.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -126.3 | −53.1 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -62.5 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$4.09 +1.49% · +$0.06
Performance −22.4% 1Y
1Y: $5.27 on 17 Oct 2025 → $4.09. High $9.56 (10 Mar 2026), low $4.03 (16 Oct 2026).
- Previous close
- $4.03
- 52-week range
- $4.03 – $9.56
- One year
- −23.26%
Overview
- Symbol
- VNDA
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Vanda earnings calls (VNDA)
Financials
What the filings say
Net profit, year on year: −130% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 48 | 53 | 50 | 53 | 56 | 57 | 52 | 51 |
| Expenses | 59 | 63 | 91 | 91 | 88 | 98 | 102 | 114 |
| Operating profit | -11 | -10 | -41 | -39 | -31 | -40 | -50 | -64 |
| Operating margin | −23.1% | −19.3% | −82.0% | −73.2% | −55.6% | −70.5% | −97.1% | −126.3% |
| Profit before tax | -6 | -6 | -37 | -35 | -28 | -38 | -48 | -62 |
| Tax rate | 14.7% | 24.4% | 21.1% | 22.0% | 20.4% | −271.5% | −0.3% | −0.2% |
| Net profit | -5 | -5 | -29 | -27 | -23 | -141 | -49 | -63 |
| EPS ($ per share) | -0.09 | — | -0.50 | -0.46 | -0.38 | — | -0.82 | -1.04 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -336 | -221 | -197 | -164 | -158 | -155 | -174 | -395 |
| Total liabilities | 57 | 73 | 80 | 89 | 107 | 104 | 118 | 162 |
| Fixed assets | 4 | 4 | 4 | 3 | 3 | 2 | 2 | 2 |
| Total assets | 332 | 484 | 533 | 594 | 634 | 648 | 656 | 489 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 30 | 46 | 52 | 64 | 32 | 13 | -16 | -109 |
| Cash from investing | -110 | -68 | -41 | -77 | 50 | -12 | -17 | 95 |
| Cash from financing | 107 | 6 | 6 | 4 | 1 | 0 | -0 | -3 |
| Net cash flow | 27 | -16 | 16 | -9 | 83 | 1 | -34 | -17 |
| Capital expenditure | -0 | -1 | -2 | -1 | -1 | -0 | -0 | -1 |
| Free cash flow | 30 | 45 | 50 | 64 | 31 | 12 | -16 | -110 |
Insider filings
20 filings between Feb 18, 2026 and Jun 4, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$2.82M
6 sales by 6 insiders
Compensation
not trading decisions- 13
- Award — granted as compensation
Also filed: 1 gift.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Polymeropoulos Mihael Hristos | — | $1.28M | Mar 2, 2026 |
| Moran Kevin Patrick | — | $350.8K | Mar 2, 2026 |
| Williams Timothy | — | $350.8K | Mar 2, 2026 |
| Birznieks Gunther | — | $350.7K | Mar 2, 2026 |
| Wijkstrom Joakim | — | $254.6K | Mar 2, 2026 |
| Honore Tage | — | $240.9K | Feb 23, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jun 4, 2026 | Honore Tage Director | Award | 41,600 | $0 |
| Jun 4, 2026 | Ward Anne Sempowski Director | Award | 41,600 | $0 |
| Jun 4, 2026 | DUGAN RICHARD W Director | Award | 41,600 | $0 |
| Jun 4, 2026 | Mitchell Stephen Ray Director | Award | 41,600 | $0 |
| Jun 4, 2026 | Duncan Charles Cliff Director | Award | 41,600 | $0 |
| Jun 4, 2026 | Chrousos Phaedra Director | Award | 41,600 | $0 |
| Jun 4, 2026 | McGuire Daniel Patrick SVP, GC and Secretary | Award | 80,000 | $0 |
| May 18, 2026 | Mitchell Stephen Ray Director | Gift | 25,836 | $0 |
| Apr 22, 2026 | Duncan Charles Cliff Director | Award | 57,101 | $0 |
| Mar 2, 2026 | Polymeropoulos Mihael Hristos President and CEO | Sale | 156,235 | $1.28M |
| Mar 2, 2026 | Birznieks Gunther SVP, Business Development | Sale | 42,431 | $350.7K |
| Mar 2, 2026 | Williams Timothy SVP & General Counsel | Sale | 42,434 | $350.8K |
| Mar 2, 2026 | Wijkstrom Joakim SVP, Chief Marketing Officer | Sale | 30,800 | $254.6K |
| Mar 2, 2026 | Moran Kevin Patrick SVP, CFO & Treasurer | Sale | 42,442 | $350.8K |
| Feb 23, 2026 | Honore Tage Director | Sale | 30,000 | $240.9K |
| Feb 18, 2026 | Polymeropoulos Mihael Hristos President and CEO | Award | 525,000 | $0 |
| Feb 18, 2026 | Moran Kevin Patrick SVP, CFO & Treasurer | Award | 125,000 | $0 |
| Feb 18, 2026 | Williams Timothy SVP & General Counsel | Award | 125,000 | $0 |
| Feb 18, 2026 | Birznieks Gunther SVP, Business Development | Award | 125,000 | $0 |
| Feb 18, 2026 | Wijkstrom Joakim SVP, Chief Marketing Officer | Award | 125,000 | $0 |
| Aug 7, 2025 | Polymeropoulos Mihael Hristos President and CEO | Purchase | 10,000 | $41.5K |
| Jun 13, 2025 | Mitchell Stephen Ray Director | Sale | 7,000 | $32.1K |
| Jun 5, 2025 | Chrousos Phaedra Director | Award | 59,225 | $0 |
| Jun 5, 2025 | Ward Anne Sempowski Director | Award | 59,225 | $0 |
| Jun 5, 2025 | Honore Tage Director | Award | 59,225 | $0 |
| Jun 5, 2025 | DUGAN RICHARD W Director | Award | 59,225 | $0 |
| Jun 5, 2025 | Mitchell Stephen Ray Director | Award | 59,225 | $0 |
| May 21, 2025 | Polymeropoulos Mihael Hristos President and CEO | Purchase | 9,519 | $41.9K |
| May 21, 2025 | Polymeropoulos Mihael Hristos President and CEO | Purchase | 481 | $2.1K |
| Mar 6, 2025 | Polymeropoulos Mihael Hristos President and CEO | Purchase | 5,000 | $25.1K |
| Mar 6, 2025 | Polymeropoulos Mihael Hristos President and CEO | Purchase | 5,000 | $25.1K |
| Mar 5, 2025 | Polymeropoulos Mihael Hristos President and CEO | Purchase | 5,000 | $25.1K |
| Mar 5, 2025 | Polymeropoulos Mihael Hristos President and CEO | Purchase | 5,000 | $25.1K |
| Mar 3, 2025 | Polymeropoulos Mihael Hristos President and CEO | Purchase | 10,000 | $47.0K |
| Mar 1, 2025 | Wijkstrom Joakim SVP, Chief Marketing Officer | Tax withheld | 15,520 | $73.9K |
| Mar 1, 2025 | Williams Timothy SVP & General Counsel | Tax withheld | 26,941 | $128.2K |
| Mar 1, 2025 | Moran Kevin Patrick SVP, CFO & Treasurer | Tax withheld | 26,941 | $128.2K |
| Mar 1, 2025 | Polymeropoulos Mihael Hristos President and CEO | Tax withheld | 95,999 | $457.0K |
| Mar 1, 2025 | Birznieks Gunther SVP, Business Development | Tax withheld | 26,941 | $128.2K |
| Feb 28, 2025 | Polymeropoulos Mihael Hristos President and CEO | Purchase | 10,000 | $47.6K |
| Feb 27, 2025 | Polymeropoulos Mihael Hristos President and CEO | Purchase | 10,000 | $47.6K |
| Feb 26, 2025 | Polymeropoulos Mihael Hristos President and CEO | Purchase | 5,000 | $23.8K |
| Feb 26, 2025 | Polymeropoulos Mihael Hristos President and CEO | Purchase | 5,000 | $23.9K |
| Feb 25, 2025 | Polymeropoulos Mihael Hristos President and CEO | Purchase | 10,000 | $44.6K |
| Feb 21, 2025 | Moran Kevin Patrick SVP, CFO & Treasurer | Purchase | 2,000 | $8.8K |
| Feb 18, 2025 | Williams Timothy SVP & General Counsel | Award | 125,000 | $0 |
| Feb 18, 2025 | Birznieks Gunther SVP, Business Development | Award | 125,000 | $0 |
| Feb 18, 2025 | Moran Kevin Patrick SVP, CFO & Treasurer | Award | 125,000 | $0 |
| Feb 18, 2025 | Polymeropoulos Mihael Hristos President and CEO | Award | 450,000 | $0 |
| Feb 18, 2025 | Wijkstrom Joakim SVP, Chief Marketing Officer | Award | 125,000 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Vanda Pharmaceuticals Inc.
Free account. Everything above stays public.
Write why you follow Vanda Pharmaceuticals Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading